News Search Results
May 21, 2026, 10:00 ET Guangzhou Lupeng/Newave Pharmaceutical Inc. Enrolled the First Patient in the Global Phase 3 ROCKET-CLL Trial Evaluating Rocbrutinib (LP-168) vs. Pirtobrutinib in R/R CLL/SLL
Designation (BTD) in China for adult patients with relapsed or refractory non-germinal center B-cell-like diffuse large B-cell lymphoma (R/R non-GCB DLBCL) who have received at least two prior lines of therapy, making it the first BTK inhibitor in China—and the only one globally—to receive such designation
More news about: Lupeng Pharmaceutical Ltd
May 15, 2026, 16:30 ET Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
malignancies;LYMPHIR administered prior to commercial CD19-directed CAR-T therapy in patients with high-risk relapsed or refractory diffuse large B-cell lymphoma (DLBCL), with positive topline safety and efficacy results; and,Continued FDA engagement on Mino-Lok®, an antibiotic lock solution to salvage
More news about: Citius Pharmaceuticals, Inc.
May 15, 2026, 16:30 ET Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
malignancies;Phase 1 trial of LYMPHIR administered prior to CAR-T therapy in patients with high-risk relapsed or refractory diffuse large B-cell lymphoma (DLBCL), with positive topline safety and efficacy results; and,Initiated evaluation of new bulk drug substance (BDS) suppliers with letter
More news about: Citius Oncology, Inc.
May 11, 2026, 07:51 ET ProBio and Curocell Achieve Key CAR-T Milestone with BLA Regulatory Approval and Commercial Readiness
CRC01). This next-generation CD19-targeted CAR-T cell therapy is developed for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This approval not only highlights Korea's growing innovation in advanced therapies but also marks a critical step towards bringing transformative
More news about: ProBio Inc.
May 04, 2026, 07:30 ET ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates
diffuse large B-cell lymphoma (DLBCL) thereafter.LOTIS-7 trial ongoing with data anticipated by year-end. The LOTIS-7 Phase 1b trial evaluating ZYNLONTA in combination with the bispecific antibody glofitamab (COLUMVI®) in patients with relapsed or refractory (r/r) DLBCL is ongoing, with expected
More news about: ADC Therapeutics SA
Apr 23, 2026, 03:00 ET MINJUVI® (tafasitamab) for Relapsed or Refractory Follicular Lymphoma Approved in Australia
in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).In Europe, Minjuvi
More news about: Specialised Therapeutics
Apr 21, 2026, 10:32 ET Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral Presentation at ASCO 2026 Annual Meeting
patients with heavily pre-treated multiple myeloma; and (iii) under accelerated approval in adult patients with diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy. XPOVIO® (also known as NEXPOVIO® in certain countries) has
More news about: Karyopharm Therapeutics Inc.
Apr 20, 2026, 10:00 ET AACR 2026 Oral Presentation: Abogen Presents Preliminary Results of ABO2203 (mRNA-Encoded CD3×CD19 TCE) from First-in-Human Clinical Study in R/R B-NHL
with a 100% complete response (CR) rate achieved in the high-dose cohort as updated by Professor Li Wang. Responses were seen across both aggressive (DLBCL) and indolent (FL, MCL, MZL) lymphomas, with a 100% ORR in follicular lymphoma.Compelling Clinical Significance and Commercial PotentialThese
More news about: Abogen
Apr 20, 2026, 10:00 ET AACR 2026 Oral Presentation: Abogen Presents Preliminary Results of ABO2203 (mRNA-Encoded CD3×CD19 TCE) from First-in-Human Clinical Study in R/R B-NHL
with a 100% complete response (CR) rate achieved in the high-dose cohort as updated by Professor Li Wang. Responses were seen across both aggressive (DLBCL) and indolent (FL, MCL, MZL) lymphomas, with a 100% ORR in follicular lymphoma.Compelling Clinical Significance and Commercial PotentialThese
More news about: Abogen
Apr 02, 2026, 06:00 ET AvenCell Therapeutics Announces First Patient Dosed in Phase I QUADvance Study with AVC-203, a Novel Allogeneic CD19/CD20 Dual-Targeting CAR-T Investigational Therapy for the Treatment of Relapsed/Refractory B-Cell Malignancies
expressing receptors CD19 and/or CD20, which are known to be expressed in nearly all B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL). The product incorporates a novel, dimerized receptor construct combining constitutive CD19/CD20 dual-targeting with AvenCell's proprietary RevCAR
More news about: AvenCell Therapeutics, Inc.
Mar 26, 2026, 09:32 ET CStone Announces 2025 Annual Results: Accelerated Expansion of Global Commercial Footprint and Efficient Advancement of Innovation Pipeline 2.0
safety profile observed in front line DLBCLWhen combined with R-CHOP in the first-line DLBCL setting, no DLTs were observed across the 50–90 μg/kg dose range, with an ORR of 100% and a complete response (CR) rate exceeding 90%. In later-line DLBCL, the combination with standard-of care therapies
More news about: CStone Pharmaceuticals
Mar 24, 2026, 07:01 ET Karyopharm Announces $30 Million Private Placement with RA Capital
indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL).Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of The Private Securities
More news about: Karyopharm Therapeutics Inc.
Mar 24, 2026, 07:00 ET Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction
patients with heavily pre-treated multiple myeloma; and (iii) under accelerated approval in adult patients with diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy. XPOVIO® (also known as NEXPOVIO® in certain countries) has
More news about: Karyopharm Therapeutics Inc.
Mar 20, 2026, 05:06 ET Antengene Announces 2025 Full-Year Results: First TCE Out-licensing Validates Platform Value and Marks Inflection Point Towards 2026 Profitability
including XPOVIO® monotherapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) and XPOVIO® in combination with dexamethasone for the treatment of R/R MM.Taiwan Market: In
More news about: Antengene Corporation Limited
Mar 10, 2026, 07:30 ET ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update
"Building off the meaningful progress achieved across our ZYNLONTA clinical program in DLBCL and through investigator-initiated trials in indolent lymphomas this past year, we believe we have laid the foundation for multiple anticipated value-creating
More news about: ADC Therapeutics SA
Mar 04, 2026, 09:15 ET Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma
296369About Diffuse Large B-Cell Lymphoma (DLBCL)Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL), accounting for approximately 30%–40% of newly diagnosed cases in the United States. DLBCL is an aggressive and rapidly growing cancer of B
More news about: Citius Oncology, Inc.
Mar 02, 2026, 16:05 ET Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit
More news about: Karyopharm Therapeutics Inc.
Mar 01, 2026, 19:30 ET XPOVIO® Receives Reimbursement Approval in South Korea for a Second Multiple Myeloma Indication
myeloma (MM).- In South Korea, XPOVIO® has been approved for three indications across MM and diffuse large B-cell lymphoma (DLBCL), and two of these approved indications have been included in the national reimbursement scheme.SHANGHAI and
More news about: Antengene Corporation Limited
Feb 23, 2026, 07:15 ET ADC Therapeutics Announces Amended HealthCare Royalty Financing Agreement
relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma. The trial included a broad spectrum of heavily pre-treated
More news about: ADC Therapeutics SA
Feb 12, 2026, 07:30 ET Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
patients with heavily pre-treated multiple myeloma; and (iii) under accelerated approval in adult patients with diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy. XPOVIO® (also known as NEXPOVIO® in certain countries) has
More news about: Karyopharm Therapeutics Inc.
Feb 05, 2026, 07:30 ET Karyopharm to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026
indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit
More news about: Karyopharm Therapeutics Inc.
Feb 04, 2026, 07:48 ET AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results
Genmab. AbbVie announced topline results from the Phase 3 EPCORE DLBCL-1 trial evaluating Epkinly compared to investigator's choice of chemoimmunotherapy in adult patients with R/R diffuse large B-cell lymphoma (DLBCL). The study demonstrated an improvement in PFS and improvements were observed
More news about: AbbVie
Feb 02, 2026, 16:05 ET Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit
More news about: Karyopharm Therapeutics Inc.
Jan 30, 2026, 10:36 ET $170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium
topline results from the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab in adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The study demonstrated improvement in progression-free survival with a hazard ratio of 0.74,
More news about: Equity Insider
Jan 22, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
combination with the bispecific antibody glofitamab (COLUMVI®) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL)." Although the press release described the data in positive terms, the press release reported that adverse events occurred in two patients, one of which
More news about: Pomerantz LLP